Effect of type-selective inhibitors on cyclic nucleotide phosphodiesterase activity and insulin secretion in the clonal insulin secreting cell line BRIN-BD11

M Ahmad, Y H Abdel-Wahab, R Tate, P R Flatt, N J Pyne, B L Furman

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

1. The cyclic nucleotide phosphodiesterases (PDEs) present in an insulin secreting cell line, BRIN - BD11, were characterized using calcium/calmodulin, IGF-1, isoenzyme-selective PDE inhibitors and RT - PCR. 2. Calmodulin activated cyclic AMP or cyclic GMP PDE activity in pellet and was 3 fold (P=0.002) more potent in activating cyclic nucleotide hydrolysis in pellet compared with supernatant fractions. 3. The PDE1/PDE5 inhibitor zaprinast inhibited both cyclic AMP and cyclic GMP PDE activity in both pellet and supernatant fractions of cell homogenates by a maximum of around 25% (IC(50) 1 - 5 microM), while rolipram (PDE4 selective) inhibited only cyclic AMP hydrolysis. 4. The PDE3-selective inhibitors Org 9935 (0.02 - 10 microM) and siguazodan (0.1 - 10 microM) inhibited cyclic AMP PDE activity in the pellet but not the supernatant fractions of cell homogenates, with a maximum inhibition of about 30%. IGF-1 (2 - 7.5 ng ml(-1)) potently augmented this PDE activity. 5. RT - PCR using specific primers for PDE3B, but not for PDE3A, amplified, from BRIN - BD11 cell total RNA, a 351 base pair product that was >97% homologous with rat adipose tissue PDE3B. 6. IBMX, Org 9935, siguazodan and rolipram (1 - 50 microM), but not zaprinast, each augmented glucose-induced insulin secretion in the presence of 16.7 mM but not 1 mM glucose. 7. These findings, in a clonal insulin secreting cell line, are consistent with an important role for PDE3B in regulating the pool of cyclic AMP relevant to the modulation of glucose-induced insulin secretion.
LanguageEnglish
Pages1228-1234
Number of pages7
JournalBritish Journal of Pharmacology
Volume129
Issue number6
DOIs
Publication statusPublished - Mar 2000

Fingerprint

Cyclic Nucleotides
Phosphoric Diester Hydrolases
Insulin-Secreting Cells
Cyclic AMP
Insulin
Cell Line
Rolipram
Cyclic GMP
Calmodulin
Insulin-Like Growth Factor I
Glucose
Hydrolysis
Phosphodiesterase 3 Inhibitors
Phosphodiesterase 5 Inhibitors
1-Methyl-3-isobutylxanthine
Polymerase Chain Reaction
Insulin-Like Growth Factor II
Phosphodiesterase Inhibitors
Base Pairing
Isoenzymes

Keywords

  • 1-Methyl-3-isobutylxanthine
  • 3',5'-Cyclic-AMP Phosphodiesterases
  • animals
  • base sequence
  • calcium
  • calmodulin
  • clone cells
  • cyclic AMP
  • cyclic nucleotide phosphodiesterases, type 1
  • glucose
  • humans
  • insulin
  • insulin-like growth factor I
  • islets of langerhans
  • molecular sequence data
  • phosphodiesterase inhibitors
  • purinones
  • rats
  • reverse transcriptase polymerase chain reaction

Cite this

@article{c68d43cf153c4cd185200cff9237a597,
title = "Effect of type-selective inhibitors on cyclic nucleotide phosphodiesterase activity and insulin secretion in the clonal insulin secreting cell line BRIN-BD11",
abstract = "1. The cyclic nucleotide phosphodiesterases (PDEs) present in an insulin secreting cell line, BRIN - BD11, were characterized using calcium/calmodulin, IGF-1, isoenzyme-selective PDE inhibitors and RT - PCR. 2. Calmodulin activated cyclic AMP or cyclic GMP PDE activity in pellet and was 3 fold (P=0.002) more potent in activating cyclic nucleotide hydrolysis in pellet compared with supernatant fractions. 3. The PDE1/PDE5 inhibitor zaprinast inhibited both cyclic AMP and cyclic GMP PDE activity in both pellet and supernatant fractions of cell homogenates by a maximum of around 25{\%} (IC(50) 1 - 5 microM), while rolipram (PDE4 selective) inhibited only cyclic AMP hydrolysis. 4. The PDE3-selective inhibitors Org 9935 (0.02 - 10 microM) and siguazodan (0.1 - 10 microM) inhibited cyclic AMP PDE activity in the pellet but not the supernatant fractions of cell homogenates, with a maximum inhibition of about 30{\%}. IGF-1 (2 - 7.5 ng ml(-1)) potently augmented this PDE activity. 5. RT - PCR using specific primers for PDE3B, but not for PDE3A, amplified, from BRIN - BD11 cell total RNA, a 351 base pair product that was >97{\%} homologous with rat adipose tissue PDE3B. 6. IBMX, Org 9935, siguazodan and rolipram (1 - 50 microM), but not zaprinast, each augmented glucose-induced insulin secretion in the presence of 16.7 mM but not 1 mM glucose. 7. These findings, in a clonal insulin secreting cell line, are consistent with an important role for PDE3B in regulating the pool of cyclic AMP relevant to the modulation of glucose-induced insulin secretion.",
keywords = "1-Methyl-3-isobutylxanthine, 3',5'-Cyclic-AMP Phosphodiesterases, animals, base sequence, calcium, calmodulin, clone cells, cyclic AMP, cyclic nucleotide phosphodiesterases, type 1, glucose, humans, insulin, insulin-like growth factor I, islets of langerhans, molecular sequence data, phosphodiesterase inhibitors, purinones, rats, reverse transcriptase polymerase chain reaction",
author = "M Ahmad and Abdel-Wahab, {Y H} and R Tate and Flatt, {P R} and Pyne, {N J} and Furman, {B L}",
year = "2000",
month = "3",
doi = "10.1038/sj.bjp.0703165",
language = "English",
volume = "129",
pages = "1228--1234",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
number = "6",

}

TY - JOUR

T1 - Effect of type-selective inhibitors on cyclic nucleotide phosphodiesterase activity and insulin secretion in the clonal insulin secreting cell line BRIN-BD11

AU - Ahmad, M

AU - Abdel-Wahab, Y H

AU - Tate, R

AU - Flatt, P R

AU - Pyne, N J

AU - Furman, B L

PY - 2000/3

Y1 - 2000/3

N2 - 1. The cyclic nucleotide phosphodiesterases (PDEs) present in an insulin secreting cell line, BRIN - BD11, were characterized using calcium/calmodulin, IGF-1, isoenzyme-selective PDE inhibitors and RT - PCR. 2. Calmodulin activated cyclic AMP or cyclic GMP PDE activity in pellet and was 3 fold (P=0.002) more potent in activating cyclic nucleotide hydrolysis in pellet compared with supernatant fractions. 3. The PDE1/PDE5 inhibitor zaprinast inhibited both cyclic AMP and cyclic GMP PDE activity in both pellet and supernatant fractions of cell homogenates by a maximum of around 25% (IC(50) 1 - 5 microM), while rolipram (PDE4 selective) inhibited only cyclic AMP hydrolysis. 4. The PDE3-selective inhibitors Org 9935 (0.02 - 10 microM) and siguazodan (0.1 - 10 microM) inhibited cyclic AMP PDE activity in the pellet but not the supernatant fractions of cell homogenates, with a maximum inhibition of about 30%. IGF-1 (2 - 7.5 ng ml(-1)) potently augmented this PDE activity. 5. RT - PCR using specific primers for PDE3B, but not for PDE3A, amplified, from BRIN - BD11 cell total RNA, a 351 base pair product that was >97% homologous with rat adipose tissue PDE3B. 6. IBMX, Org 9935, siguazodan and rolipram (1 - 50 microM), but not zaprinast, each augmented glucose-induced insulin secretion in the presence of 16.7 mM but not 1 mM glucose. 7. These findings, in a clonal insulin secreting cell line, are consistent with an important role for PDE3B in regulating the pool of cyclic AMP relevant to the modulation of glucose-induced insulin secretion.

AB - 1. The cyclic nucleotide phosphodiesterases (PDEs) present in an insulin secreting cell line, BRIN - BD11, were characterized using calcium/calmodulin, IGF-1, isoenzyme-selective PDE inhibitors and RT - PCR. 2. Calmodulin activated cyclic AMP or cyclic GMP PDE activity in pellet and was 3 fold (P=0.002) more potent in activating cyclic nucleotide hydrolysis in pellet compared with supernatant fractions. 3. The PDE1/PDE5 inhibitor zaprinast inhibited both cyclic AMP and cyclic GMP PDE activity in both pellet and supernatant fractions of cell homogenates by a maximum of around 25% (IC(50) 1 - 5 microM), while rolipram (PDE4 selective) inhibited only cyclic AMP hydrolysis. 4. The PDE3-selective inhibitors Org 9935 (0.02 - 10 microM) and siguazodan (0.1 - 10 microM) inhibited cyclic AMP PDE activity in the pellet but not the supernatant fractions of cell homogenates, with a maximum inhibition of about 30%. IGF-1 (2 - 7.5 ng ml(-1)) potently augmented this PDE activity. 5. RT - PCR using specific primers for PDE3B, but not for PDE3A, amplified, from BRIN - BD11 cell total RNA, a 351 base pair product that was >97% homologous with rat adipose tissue PDE3B. 6. IBMX, Org 9935, siguazodan and rolipram (1 - 50 microM), but not zaprinast, each augmented glucose-induced insulin secretion in the presence of 16.7 mM but not 1 mM glucose. 7. These findings, in a clonal insulin secreting cell line, are consistent with an important role for PDE3B in regulating the pool of cyclic AMP relevant to the modulation of glucose-induced insulin secretion.

KW - 1-Methyl-3-isobutylxanthine

KW - 3',5'-Cyclic-AMP Phosphodiesterases

KW - animals

KW - base sequence

KW - calcium

KW - calmodulin

KW - clone cells

KW - cyclic AMP

KW - cyclic nucleotide phosphodiesterases, type 1

KW - glucose

KW - humans

KW - insulin

KW - insulin-like growth factor I

KW - islets of langerhans

KW - molecular sequence data

KW - phosphodiesterase inhibitors

KW - purinones

KW - rats

KW - reverse transcriptase polymerase chain reaction

U2 - 10.1038/sj.bjp.0703165

DO - 10.1038/sj.bjp.0703165

M3 - Article

VL - 129

SP - 1228

EP - 1234

JO - British Journal of Pharmacology

T2 - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 6

ER -